[go: up one dir, main page]

PL2560662T3 - Sulodeksyd do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy - Google Patents

Sulodeksyd do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy

Info

Publication number
PL2560662T3
PL2560662T3 PL11723652T PL11723652T PL2560662T3 PL 2560662 T3 PL2560662 T3 PL 2560662T3 PL 11723652 T PL11723652 T PL 11723652T PL 11723652 T PL11723652 T PL 11723652T PL 2560662 T3 PL2560662 T3 PL 2560662T3
Authority
PL
Poland
Prior art keywords
sulodexide
metalloproteinases
pathologies
involved
treatment
Prior art date
Application number
PL11723652T
Other languages
English (en)
Inventor
Giuseppe Claudio Viscomi
Ferdinando Mannello
Cristiana Bruno
Original Assignee
Alfa Wassermann S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2560662(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann S.P.A. filed Critical Alfa Wassermann S.P.A.
Publication of PL2560662T3 publication Critical patent/PL2560662T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/38Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11723652T 2010-04-23 2011-04-20 Sulodeksyd do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy PL2560662T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITBO2010A000250A IT1401253B1 (it) 2010-04-23 2010-04-23 Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.

Publications (1)

Publication Number Publication Date
PL2560662T3 true PL2560662T3 (pl) 2017-09-29

Family

ID=43063923

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13161007T PL2609925T3 (pl) 2010-04-23 2011-04-20 Siarczan dermatanu do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy
PL11723652T PL2560662T3 (pl) 2010-04-23 2011-04-20 Sulodeksyd do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13161007T PL2609925T3 (pl) 2010-04-23 2011-04-20 Siarczan dermatanu do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy

Country Status (11)

Country Link
US (1) US8987231B2 (pl)
EP (2) EP2560662B1 (pl)
KR (2) KR20160060164A (pl)
CN (1) CN102883728A (pl)
ES (2) ES2694587T3 (pl)
IT (1) IT1401253B1 (pl)
MX (1) MX339537B (pl)
PL (2) PL2609925T3 (pl)
PT (2) PT2560662T (pl)
RU (1) RU2557996C2 (pl)
WO (1) WO2011132161A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
WO2015059177A1 (en) * 2013-10-22 2015-04-30 Cell Receptor Ug Sulfated polysaccharides for use in the treatment of cancer
CN104398533B (zh) * 2014-11-26 2017-03-08 山东辰中生物制药有限公司 舒洛地特的生产方法
RU2667650C1 (ru) * 2017-12-15 2018-09-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения и профилактики острого тромбоза геморроидальных узлов

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2426586A1 (de) 1973-06-14 1975-01-09 Opocrin Srl Verfahren zur herstellung von glukuronil-glukosamin-glykan-sulfaten mit antilipaemischer wirkung
US4705798A (en) 1985-09-27 1987-11-10 University Of Iowa Research Foundation Phenylephrine prodrug useful as mydriatic agent
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
IT1242604B (it) * 1990-11-13 1994-05-16 Alfa Wassermann Spa Sali di glicosaminoglicani con esteri di aminoacidi, loro preparazione e formulazioni farmaceutiche che li contengono.
IT1245907B (it) * 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
KR950704362A (ko) 1993-09-30 1995-11-20 야마야 구따루 항혈전제
IT1274351B (it) 1994-10-06 1997-07-17 Alfa Wassermann Spa Uso di alcuni glicosaminoglicani nella dialisi peritoneale.
GEP20012388B (en) 1995-12-08 2001-03-25 Agouron Pharma Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
IT1285546B1 (it) * 1996-01-16 1998-06-18 Alfa Wassermann Spa Uso del dermatano solfato a basso peso molecolare e delle specialita' medicinali che lo contengono nella terapia e nella prevenzione della
IT1299969B1 (it) * 1998-04-15 2000-04-04 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della retinopatia diabetica.
ATE320261T1 (de) 1998-10-01 2006-04-15 Giovanni Gambaro Substanzen zur vorbeugung von krankhafter tgf- beta überexpression und methoden derer ermittlung
US20040009952A1 (en) 1998-10-19 2004-01-15 Giovanni Gambaro TGF-beta gene overexpression preventing substances for the treatment of disorders connected with pathological overexpression of TGF-beta
IL127896A0 (en) 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
US20090325876A1 (en) * 2004-09-29 2009-12-31 Saul Yedgar Use of lipid conjugates in the treatment of diseases associated with vasculature
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
AU2002221935A1 (en) 2000-12-16 2002-06-24 Aventis Pharma Deutschland Gmbh Use of low molecular heparin for treating osteoarthritis
FR2864087B1 (fr) 2003-12-19 2006-01-27 Aventis Pharma Sa Derives carboxy-reduits du dermatan sulfate, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant
KR100808131B1 (ko) * 2006-06-22 2008-02-29 부경대학교 산학협력단 인간 섬유육종 세포에서 메트릭스 메탈로프로테이나제-9의발현을 억제시키는 카복실화 키토올리고사카라이드 화합물및 이를 함유한 메트릭스 메탈로프로테이나제-9 억제제
CN101632686A (zh) * 2008-04-04 2010-01-27 马斯特里赫特大学 糖胺聚糖用于修复糖萼的用途
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity

Also Published As

Publication number Publication date
EP2609925A2 (en) 2013-07-03
EP2560662B1 (en) 2017-06-07
US20130045946A1 (en) 2013-02-21
ITBO20100250A1 (it) 2011-10-24
RU2557996C2 (ru) 2015-07-27
PL2609925T3 (pl) 2019-02-28
EP2560662A2 (en) 2013-02-27
KR101739757B1 (ko) 2017-05-25
IT1401253B1 (it) 2013-07-18
KR20130072199A (ko) 2013-07-01
US8987231B2 (en) 2015-03-24
MX2012012285A (es) 2012-11-23
PT2560662T (pt) 2017-07-10
MX339537B (es) 2016-05-30
KR20160060164A (ko) 2016-05-27
CN102883728A (zh) 2013-01-16
PT2609925T (pt) 2018-11-22
WO2011132161A3 (en) 2012-03-08
EP2609925B1 (en) 2018-10-17
WO2011132161A2 (en) 2011-10-27
ES2694587T3 (es) 2018-12-21
RU2012142256A (ru) 2014-05-27
ES2628582T3 (es) 2017-08-03
EP2609925A3 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
HRP20181615T1 (hr) Terapijsko sredstvo koje izaziva citotoksičnost
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
GB2491118B (en) Cannabinoids for use in the treatment of neuropathic pain
EP2670434A4 (en) TREATMENT OF TAUOPATHIA
PL2652193T3 (pl) Obróbka
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
PT2694107T (pt) Tratamento para patologias dermatológicas
HK1210585A1 (en) Alpha-1-microglobulin for use in the treatment of mitochondria- related diseases -1
IL225896A0 (en) Treatment of mecp-2 related disorders
GB2496688B (en) Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
PL2560662T3 (pl) Sulodeksyd do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy
GB201013573D0 (en) Treatment
IL232239A0 (en) Medical use
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
GB201016486D0 (en) Compounds for the use in treatment of plants
PL2456445T3 (pl) Środek do leczenia chorób skóry
GB201014097D0 (en) Treatment
GB201013068D0 (en) Liquid treatment
GB201105302D0 (en) Treatment of acidosis
GB201001659D0 (en) Body treatment product
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
GB201021319D0 (en) Treatment